Hepatitis B Virus News and Research

RSS

'Simple' model predicts PegIFN response in chronic HBV

Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.

23 Jun 2016

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate.

23 Jun 2016

Maternal HBsAg can serve as HBV vertical transmission marker

Two studies have independently identified quantitative hepatitis B surface antigen as a marker to identify pregnant women with chronic hepatitis B virus infection whose infants are at high-risk of infection despite immunoprophylaxis.

23 Jun 2016

First CRISPR/Cas9 screen helps identify human proteins required for Zika virus replication

Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.

22 Jun 2016

Portal vein hypertension diminishes after hepatitis C recovery

This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein.

15 Jun 2016

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable.

8 Jun 2016

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases.

7 Jun 2016

Research sheds light on potential impact of HCV treatment in preventing virus transmission

An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV).

19 May 2016

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.

17 May 2016

New study sheds more light on level of alcohol consumption among people with hepatitis C

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use.

11 May 2016

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology.

5 May 2016

Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer.

3 May 2016

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection.

27 Apr 2016

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

27 Apr 2016

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers.

27 Apr 2016

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

New blood treatment technology could reduce malaria risk following blood transfusions

Patients, especially children, who undergo blood transfusions in sub-Saharan Africa are at high risk of transfusion-transmitted malaria. A new trial, published in The Lancet today, suggests that treating donated blood with a new technology that combines UV radiation and vitamin B is safe and could minimise the risk of malaria infection following blood transfusions.

26 Apr 2016

Resolving HBV infection does not reduce liver cancer risk

Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.

25 Apr 2016

Johns Hopkins study suggests updated universal screening for hepatitis C virus

A review of blood samples for nearly 5,000 patients seen at The Johns Hopkins Hospital Emergency Department suggests that federal guidelines for hepatitis C virus (HCV) screening may be missing up to a quarter of all cases and argues for updated universal screening.

15 Apr 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

Hepatitis B Virus News and Research

'Simple' model predicts PegIFN response in chronic HBV

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

Maternal HBsAg can serve as HBV vertical transmission marker

First CRISPR/Cas9 screen helps identify human proteins required for Zika virus replication

Portal vein hypertension diminishes after hepatitis C recovery

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Research sheds light on potential impact of HCV treatment in preventing virus transmission

Experimental hepatitis C drug slows down development of Zika in mice

New study sheds more light on level of alcohol consumption among people with hepatitis C

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

HBcrAg may predict HCC development

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Regular aspirin use may help reduce risk of bile duct cancer

New blood treatment technology could reduce malaria risk following blood transfusions

Resolving HBV infection does not reduce liver cancer risk

Johns Hopkins study suggests updated universal screening for hepatitis C virus

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News